{"DataElement":{"publicId":"7171854","version":"2","preferredName":"Patient No RECIST Version 1.1 Measurable Lesion Or Disease Clinical Trial Eligibility Criteria Confirmation Status","preferredDefinition":"The status of patient eligibility verification for the requirements of no RESIST 1.1 measurable lesions or diseases as outlined in the study protocol.","longName":"ELIG_NO_RECIST_MLES_OR_DZ_CONF","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"7169287","version":"1","preferredName":"Patient Negation Response Evaluation Criteria in Solid Tumors Version 1.1 Measurable Lesion Or Disease or Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An operation in which a term denies or inverts the meaning of another term or construction._A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000 and revised in 2009, which is an objective response criteria used to assess solid tumor response and to measure change in tumor size for use in adult and pediatric cancer clinical trials. Major revisions in RECIST version 1.1 includes lymph node (LN) measurement, the maximum number of target lesions, the definition of disease progression, as well as the inclusion of and guidance on the use of MRI and FDG PET in the detection of new lesions._A finding indicating that a localized pathological lesion can be measured in at least one dimension._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2177068v1.0:7171845v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7171845","version":"1","preferredName":"Negation Response Evaluation Criteria in Solid Tumors Version 1.1 Measurable Lesion Or Disease or Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.:A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000 and revised in 2009, which is an objective response criteria used to assess solid tumor response and to measure change in tumor size for use in adult and pediatric cancer clinical trials. Major revisions in RECIST version 1.1 includes lymph node (LN) measurement, the maximum number of target lesions, the definition of disease progression, as well as the inclusion of and guidance on the use of MRI and FDG PET in the detection of new lesions.:A finding indicating that a localized pathological lesion can be measured in at least one dimension.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"7171845v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Response Evaluation Criteria in Solid Tumors Version 1.1","conceptCode":"C124415","definition":"A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000 and revised in 2009, which is an objective response criteria used to assess solid tumor response and to measure change in tumor size for use in adult and pediatric cancer clinical trials. Major revisions in RECIST version 1.1 includes lymph node (LN) measurement, the maximum number of target lesions, the definition of disease progression, as well as the inclusion of and guidance on the use of MRI and FDG PET in the detection of new lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Measurable Lesion","conceptCode":"C167209","definition":"A finding indicating that a localized pathological lesion can be measured in at least one dimension.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9ECA7FFB-E3FF-09A5-E053-F662850A2AC7","latestVersionIndicator":"Yes","beginDate":"2020-02-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-17","modifiedBy":"ONEDATA","dateModified":"2020-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8B9012-2CA9-4979-E053-F662850AFE69","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-14","modifiedBy":"TAYLORT","dateModified":"2020-02-26","changeDescription":"2/14/20 EA1183/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5676955","version":"2","preferredName":"Confirmation Status","preferredDefinition":"Having been established or verified._A condition or state at a particular time.","longName":"CONFSTAT","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"11","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unconfirmed","valueDescription":"Negation Confirmation","ValueMeaning":{"publicId":"5676956","version":"1","preferredName":"Negation Confirmation","longName":"5676956","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Having been established or verified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49380D88-AB51-745A-E053-F662850AA135","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE40-165A-E053-4EBD850AA952","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"},{"value":"Confirmed","valueDescription":"Confirmation","ValueMeaning":{"publicId":"3953314","version":"1","preferredName":"Confirmation","longName":"3953314","preferredDefinition":"Having been established or verified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A874-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"RODGERSC","dateCreated":"2013-11-18","modifiedBy":"TSESU","dateModified":"2019-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE4A-165A-E053-4EBD850AA952","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"},{"value":"N/A","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE54-165A-E053-4EBD850AA952","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7329879","version":"1","preferredName":"Confirmation Status","preferredDefinition":"Having been established or verified.:A condition or state at a particular time.","longName":"C25458:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BA8394-AE19-165A-E053-4EBD850AA952","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BA8394-AE2A-165A-E053-4EBD850AA952","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"TAYLORT","dateModified":"2020-06-12","changeDescription":"6/10/20 tmt versioned to 2.0 for changes to Long and Short names.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient does not have RECIST","type":"Preferred Question Text","description":"Patient does not have RECIST 1.1 measurable lesions in viscera, active central nervous system (CNS), leptomeningeal carcinomatous or pleural or peritoneal disease.","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D47EF8-5DAD-7BE8-E053-4EBD850A2C26","latestVersionIndicator":"Yes","beginDate":"2020-02-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-11","modifiedBy":"TAYLORT","dateModified":"2020-06-12","changeDescription":"6/11/20 CDE versioned for updated VD;edit to LN tmt. 2/26/20 tmt released.; 2/17/20 EA1183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}